Breast Cancer Clinical Trial
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
Summary
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.
Eligibility Criteria
Key Inclusion Criteria:
Age > 18 years, with residual invasive triple negative breast cancer (TNBC) in the breast or lymph nodes after neoadjuvant therapy and surgery:
TNBC criteria for the study is defined as estrogen receptor (ER) and progesterone receptor (PR) < 10%, human epidermal growth factor receptor 2 (HER2)-negative per American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) guidelines (immunohistochemistry (IHC) and/or in situ hybridization (ISH)).
Adequate excision and surgical removal of all clinically evident of disease in the breast and/or lymph nodes and have adequately recovered from surgery.
Submission of both pre-neoadjuvant treatment diagnostic biopsy and resected residual invasive disease tissue.
Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
Individuals must have received appropriate radiotherapy and have recovered prior to starting study treatment.
Adequate organ function.
Key Exclusion Criteria:
Stage IV (metastatic) breast cancer as well as history of any prior (ipsi- or contralateral) invasive breast cancer.
Prior treatment with another stimulatory or coinhibitory T-cell receptor agent (eg, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), OX-40, cluster of differentiation 137 (CD137), prior treatment with any HER2-directed agent.
Evidence of recurrent disease following preoperative therapy and surgery.
Prior treatment with topoisomerase 1 inhibitors or antibody-drug conjugates (ADCs) containing a topoisomerase inhibitor.
Individuals with known germline breast cancer gene (BRCA) mutations.
Myocardial infarction or unstable angina pectoris within 6 months of enrollment or history of serious ventricular arrhythmia (ie, ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias or Left ventricular ejection fraction (LVEF) of < 50%
Active serious infections requiring anti-microbial therapy.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 111 Locations for this study
Birmingham Alabama, 35243, United States
Huntsville Alabama, 35805, United States
Glendale Arizona, 85304, United States
Prescott Valley Arizona, 86314, United States
Downey California, 90241, United States
Fountain Valley California, 92708, United States
Los Angeles California, 90017, United States
Redlands California, 92373, United States
Sacramento California, 95816, United States
San Francisco California, 94143, United States
Santa Barbara California, 93105, United States
Stockton California, 95204, United States
Danbury Connecticut, 06810, United States
Stamford Connecticut, 06902, United States
Clearwater Florida, 00337, United States
Jacksonville Florida, 32256, United States
Jupiter Florida, 33458, United States
Miami Beach Florida, 33140, United States
Orange City Florida, 32763, United States
Orlando Florida, 32806, United States
Palm Bay Florida, 32909, United States
Pensacola Florida, 32504, United States
Tampa Florida, 33614, United States
Athens Georgia, 30607, United States
Atlanta Georgia, 30318, United States
Atlanta Georgia, 30342, United States
Marietta Georgia, 30060, United States
Valdosta Georgia, 31602, United States
Boise Idaho, 83712, United States
Coeur d'Alene Idaho, 83814, United States
Chicago Illinois, 60612, United States
Evanston Illinois, 60201, United States
Naperville Illinois, 60540, United States
River Forest Illinois, 60305, United States
Skokie Illinois, 60076, United States
Springfield Illinois, 62702, United States
Indianapolis Indiana, 46260, United States
Lafayette Indiana, 47904, United States
Cedar Rapids Iowa, 52403, United States
Des Moines Iowa, 50309, United States
Lexington Kentucky, 40536, United States
Louisville Kentucky, 40207, United States
Paducah Kentucky, 42003, United States
Baton Rouge Louisiana, 70809, United States
New Orleans Louisiana, 70112, United States
Scarborough Maine, 04074, United States
Baltimore Maryland, 21215, United States
Baltimore Maryland, 21229, United States
Baltimore Maryland, 21231, United States
Baltimore Maryland, 21237, United States
Bethesda Maryland, 20817, United States
Frederick Maryland, 21702, United States
Towson Maryland, 21204, United States
Boston Massachusetts, 02215, United States
Grand Rapids Michigan, 49503, United States
Southfield Michigan, 48075, United States
Minneapolis Minnesota, 55407, United States
Saint Louis Park Minnesota, 55426, United States
Saint Louis Missouri, 63131, United States
Hastings Nebraska, 68901, United States
Omaha Nebraska, 68114, United States
Omaha Nebraska, 68124, United States
East Brunswick New Jersey, 08816, United States
Flemington New Jersey, 08822, United States
Florham Park New Jersey, 07932, United States
New Brunswick New Jersey, 08901, United States
Summit New Jersey, 07901, United States
Albuquerque New Mexico, 87131, United States
Farmington New Mexico, 87401, United States
Amsterdam New York, 12010, United States
Bronx New York, 10467, United States
East Syracuse New York, 13057, United States
New York New York, 10016, United States
Rochester New York, 14618, United States
Shirley New York, 11967, United States
Stony Brook New York, 11794, United States
Westbury New York, 11590, United States
White Plains New York, 10601, United States
Pinehurst North Carolina, 28374, United States
Raleigh North Carolina, 27607, United States
Cincinnati Ohio, 45220, United States
Cincinnati Ohio, 45242, United States
Columbus Ohio, 43214, United States
Columbus Ohio, 43221, United States
Middletown Ohio, 45042, United States
Toledo Ohio, 43623, United States
Corvallis Oregon, 97330, United States
Eugene Oregon, 97401, United States
Portland Oregon, 97213, United States
Lancaster Pennsylvania, 17601, United States
Philadelphia Pennsylvania, 19104, United States
Sayre Pennsylvania, 18840, United States
West Reading Pennsylvania, 19611, United States
York Pennsylvania, 17403, United States
Providence Rhode Island, 02905, United States
Rapid City South Dakota, 57701, United States
Sioux Falls South Dakota, 57105, United States
Knoxville Tennessee, 37909, United States
Knoxville Tennessee, 37920, United States
Austin Texas, 78731, United States
Houston Texas, 77030, United States
Lubbock Texas, 79410, United States
San Antonio Texas, 78240, United States
Salt Lake City Utah, 84112, United States
Charlottesville Virginia, 22908, United States
Richmond Virginia, 23298, United States
Roanoke Virginia, 24014, United States
Lacey Washington, 98503, United States
Puyallup Washington, 98373, United States
Renton Washington, 98055, United States
Spokane Washington, 99208, United States
How clear is this clinincal trial information?